Literature DB >> 3614010

Lithium and viruses.

R O Bach.   

Abstract

The activity of the lithium ion against DNA type viruses is explained by its competition with magnesium ions. Magnesium acts as the cofactor of the enzymes responsible for the replicative building of viral proteins and nucleosides. When lithium replaces magnesium, it appears to render the polymerase enzymes impotent. Association constants for lithium and magnesium with ATP, a pertinent model substance, are of the same order of magnitude, which shows that interference must occur. Some chelating agents such as PAA have antiviral properties, and their action can be explained also if the delta G of their binding of magnesium is more negative than that of magnesium with ATP. This again displaces the magnesium as the enzymatic cofactor, thereby halting viral replication.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3614010     DOI: 10.1016/0306-9877(87)90152-6

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  2 in total

1.  Lithium as a candidate treatment for COVID-19: Promises and pitfalls.

Authors:  Ravi Philip Rajkumar
Journal:  Drug Dev Res       Date:  2020-06-10       Impact factor: 4.360

2.  Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.

Authors:  Carlos Spuch; Marta López-García; Tania Rivera-Baltanás; Daniela Rodrígues-Amorím; José M Olivares
Journal:  Front Pharmacol       Date:  2020-08-27       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.